Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice

por Violet, J A, Dearling, J L J, Green, A J, Begent, R H J, Pedley, R B
Publicado 2008

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments

por Casey, J L, Pedley, R B, King, D J, Green, A J, Yarranton, G T, Begent, R H J
Publicado 1999

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

por Webley, S D, Francis, R J, Pedley, R B, Sharma, S K, Begent, R H J, Hartley, J A, Hochhauser, D
Publicado 2001

Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study

por Gaffan, J, Holden, L, Newlands, E S, Short, D, Fuller, S, Begent, R H J, Rustin, G J S, Seckl, M J
Publicado 2003

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

por Mayer, A, Sharma, S K, Tolner, B, Minton, N P, Purdy, D, Amlot, P, Tharakan, G, Begent, R H J, Chester, K A
Publicado 2004

In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines

por Al-Mufti, R A M, Pedley, R B, Marshall, D, Begent, R H J, Hilson, A, Winslet, M C, Hobbs, K E F
Publicado 1999

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models

por El-Emir, E, Dearling, J L J, Huhalov, A, Robson, M P, Boxer, G, Neri, D, van Dongen, G A M S, Trachsel, E, Begent, R H J, Pedley, R B
Publicado 2007

Clinical Applications of Phage-Derived sFvs and sFv Fusion Proteins

por Chester, K. A., Bhatia, J., Boxer, G., Cooke, S. P., Flynn, A. A., Huhalov, A., Mayer, A., Pedley, R. B., Robson, L., Sharma, S. K., Spencer, D. I. R., Begent, R. H. J.
Publicado 2000

Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study

por Casey, J L, Napier, M P, King, D J, Pedley, R B, Chaplin, L C, Weir, N, Skelton, L, Green, A J, Hope-Stone, L D, Yarranton, G T, Begent, R H J
Publicado 2002

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

por Francis, R J, Sharma, S K, Springer, C, Green, A J, Hope-Stone, L D, Sena, L, Martin, J, Adamson, K L, Robbins, A, Gumbrell, L, O'Malley, D, Tsiompanou, E, Shahbakhti, H, Webley, S, Hochhauser, D, Hilson, A J, Blakey, D, Begent, R H J
Publicado 2002